Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AnGes MG Alters Global Collategene Strategy, Initial Focus Now on US
June 21, 2016
- Mitsubishi Tanabe Files US NDA for ALS Drug Edaravone, Eyes Nod by March-End
June 21, 2016
- Jannie Oosthuizen to Lead MSD Japan from July
June 21, 2016
- Cyramza Earns Lung Cancer Indication in Japan
June 21, 2016
- Co-Dio AG Makes Debut; Kipres, Ecard AGs to Hit Market Early September
June 20, 2016
- AMED-Backed Neuropathic Pain Drug Now in PI: Nippon Chemiphar, Kyushu University
June 20, 2016
- Takeda Gains Access to US Cancer Genomic Network
June 20, 2016
- Takeda’s Partnership with Tri-I TDI Now Encompasses Antibody Drug Discovery
June 20, 2016
- Novartis Seeks Chronic Hives Indication for Xolair
June 20, 2016
- Aspen Japan Looks to Expand Biz through Essential Drugs, AGs: President
June 20, 2016
- Jardiance Reduces Kidney Disease Risks Too, by 39%
June 17, 2016
- Eisai to Book 9.2 Billion Yen Gain from EA Pharma Share Acquisition
June 17, 2016
- AnGes MG to License Oral CIN Therapeutic Vaccine to Morishita Jintan
June 17, 2016
- PeptiDream’s Macrocyclic Compound Advances to Clinical Stage
June 16, 2016
- Seikagaku Licenses Lumbar Disc Herniation Drug to Ferring
June 16, 2016
- Selexipag Reaches European Soil, Now Available in Germany: Nippon Shinyaku
June 16, 2016
- Novartis Japan to Revamp Ophthalmology Drug Biz amid Global Drive
June 16, 2016
- Roche to Top Global Drug Maker Ranking in 2020, Consulting Firm Predicts
June 16, 2016
- Merck Serono Can Catch Up with Rivals in Immuno-Oncology Space: Japan Oncology Head
June 16, 2016
- Eisai’s Anti-Fractalkine Antibody Suggests Safety in RA
June 15, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…